Transcription Factors Synergistically Activated at the Crossing of the Restriction Point between G1 and S Cell Cycle Phases. Pathologic Gate Opening during Multi-Hit Malignant Transformation
暂无分享,去创建一个
L. Tortolina | N. Castagnino | A. Ballestrero | F. Patrone | S. Parodi | G. Zoppoli | A. Nencioni | Massimo E. Maffei | D. Piras
[1] Silvio Parodi,et al. Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial , 2016, Wiley interdisciplinary reviews. Systems biology and medicine.
[2] Bert Vogelstein,et al. The Path to Cancer --Three Strikes and You're Out. , 2015, The New England journal of medicine.
[3] T. M. Harrison,et al. Potentially biogenic carbon preserved in a 4.1 billion-year-old zircon , 2015, Proceedings of the National Academy of Sciences.
[4] M. Nowak,et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers , 2015, Nature Communications.
[5] Hans Clevers,et al. Sequential cancer mutations in cultured human intestinal stem cells , 2015, Nature.
[6] Takanori Kanai,et al. Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids , 2015, Nature Medicine.
[7] T. Yap,et al. Combining targeted therapeutics in the era of precision medicine , 2015, British Journal of Cancer.
[8] Annalisa Barla,et al. Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies , 2014, Oncotarget.
[9] Sreeurpa Ray,et al. The Cell: A Molecular Approach , 1996 .
[10] A. Bardelli,et al. Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.
[11] T. Filtz,et al. Regulation of transcription factor activity by interconnected post-translational modifications. , 2014, Trends in pharmacological sciences.
[12] J. Slingerland,et al. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy , 2013, Nature Reviews Cancer.
[13] J. Slingerland,et al. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy , 2013, Nature Reviews Cancer.
[14] Ariana Peck,et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers , 2013, Nature.
[15] J. Skotheim,et al. Control of cell cycle transcription during G1 and S phases , 2013, Nature Reviews Molecular Cell Biology.
[16] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[17] C. Glass,et al. Signaling by nuclear receptors. , 2001, Cold Spring Harbor perspectives in biology.
[18] Annalisa Barla,et al. Parameter space exploration within dynamic simulations of signaling networks. , 2012, Mathematical biosciences and engineering : MBE.
[19] J. Massagué. TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.
[20] Kevin Y. Yip,et al. Understanding transcriptional regulation by integrative analysis of transcription factor binding data , 2012, Genome research.
[21] Scott A. Busby,et al. Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. , 2012, Chemistry & biology.
[22] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[23] Hans Clevers,et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.
[24] Hans Clevers,et al. Isolation and in vitro expansion of human colonic stem cells , 2011, Nature Medicine.
[25] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[26] D. A. Foster,et al. Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s). , 2010, Genes & cancer.
[27] Jarosław Młynarczuk,et al. The role of the orphan receptor SF-1 in the development and function of the ovary. , 2010, Reproductive biology.
[28] S Parodi,et al. Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results. , 2010, Current cancer drug targets.
[29] Albertha J. M. Walhout,et al. The interplay between transcription factors and microRNAs in genome‐scale regulatory networks , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.
[30] Juan M. Vaquerizas,et al. A census of human transcription factors: function, expression and evolution , 2009, Nature Reviews Genetics.
[31] Yanhong Shi,et al. Orphan nuclear receptors in drug discovery. , 2007, Drug discovery today.
[32] Vincent Laudet,et al. Overview of Nomenclature of Nuclear Receptors , 2006, Pharmacological Reviews.
[33] J. Weinstein,et al. Depicting combinatorial complexity with the molecular interaction map notation , 2006, Molecular systems biology.
[34] A. Joe,et al. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.
[35] J. Massagué,et al. Smad transcription factors. , 2005, Genes & development.
[36] J. Weinstein,et al. Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. , 2005, Molecular biology of the cell.
[37] Vincent Laudet,et al. Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.
[38] K. Helin,et al. E2F target genes: unraveling the biology. , 2004, Trends in biochemical sciences.
[39] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[40] Weiya Ma,et al. Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. , 2004, Cancer research.
[41] Richard A Gibbs,et al. Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome. , 2004, Genome research.
[42] John N Weinstein,et al. Molecular Interaction Maps--A Diagrammatic Graphical Language for Bioregulatory Networks , 2004, Science's STKE.
[43] J. Boonstra. Progression through the G1‐phase of the on‐going cell cycle , 2003, Journal of cellular biochemistry.
[44] Steven F. Dowdy,et al. Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes , 2002 .
[45] Ken Yagi,et al. c-myc Is a Downstream Target of the Smad Pathway* 210 , 2002, The Journal of Biological Chemistry.
[46] R. Evans,et al. Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.
[47] J. Olefsky,et al. Nuclear Receptor Minireview Series* , 2001, The Journal of Biological Chemistry.
[48] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[49] K. Kohn. Molecular interaction map of the mammalian cell cycle control and DNA repair systems. , 1999, Molecular biology of the cell.
[50] Bert Vogelstein,et al. Gatekeepers and caretakers , 1997, Nature.
[51] K. Umesono,et al. The nuclear receptor superfamily: The second decade , 1995, Cell.
[52] D. Reisman,et al. Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. , 1995, Oncogene.
[53] I. McEwan. The Nuclear Receptor Superfamily at Thirty. , 2016, Methods in molecular biology.
[54] L. Tortolina,et al. Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. , 2016, Methods in molecular biology.
[55] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[56] A. Joe,et al. Oncogene addiction. , 2008, Cancer research.
[57] Steven F Dowdy,et al. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. , 2002, Current opinion in genetics & development.
[58] H. Lodish,et al. RNA Polymerase II Transcription-Initiation Complex , 2000 .